EE690 Assessing the Relative Budget Impact (BI) of PARP Inhibitor (PARPi) Combination Therapies for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) with and Without BRCA1/2 Mutations
Abstract
Authors
M. Gomez Montero C. Capone F. Kroi P. Wigfield C. Dalibot P. Robinson